ReviewNeuro-oncology2019
Novel methods to diagnose leptomeningeal metastases in breast cancer.
Review in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Re-evaluation of cerebrospinal fluid cytology for diagnosis of leptomeningeal metastasis based on radiological features, patient symptoms/signs, and clinical follow-up.Journal of neuro-oncology · 2026Article
- Leptomeningeal metastasis in triple-negative breast cancer: a retrospective study.Discover oncology · 2025Article
- Serum exosomal miRNA contributes to the diagnosis of leptomeningeal carcinomatosis.Journal of neuro-oncology · 2025Article
- Impact of Clinical Examination and Gamma Knife Surgery in Stage IV Breast Cancer With Brain Metastasis.Cureus · 2024Article
- The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.Journal of cancer research and clinical oncology · 2023Article
- Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature.Frontiers in oncology · 2023Review
- Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease.Journal of neuro-oncology · 2022Review
- Autocrine GMCSF Signaling Contributes to Growth of HER2Cancer research · 2021Article
- Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors.Journal for immunotherapy of cancer · 2021Article
- Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review.CNS oncology · 2020Review
- Management of Brain and Leptomeningeal Metastases from Breast Cancer.International journal of molecular sciences · 2020Review
- Breast leptomeningeal disease: a review of current practices and updates on management.Breast cancer research and treatment · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastases (LM) in breast cancer patients are rare but often accompanied by devastating neurological symptoms and carry a very poor prognosis, even if treated. To date, two diagnostic methods are clinically used to diagnose LM: gadolinium MRI of the brain and/or spinal cord and cytological examination of cerebrospinal fluid (CSF). Both techniques are, however, hampered by limited sensitivities, often leading to a long diagnostic process requiring repeated lumbar punctures and MRI examinations. To improve the detection rate of LM, numerous studies have assessed new techniques. In this review, we present the current workup to diagnose LM, set out an overview of novel techniques to diagnose LM, and give recommendations for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.